Skip to Content

ceftriaxone FDA Alerts

The FDA Alert(s) below may be specifically about ceftriaxone or relate to a group or class of drugs which include ceftriaxone.

MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.

Recent FDA Alert(s) for ceftriaxone

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Jan 5, 2019

Audience: Consumer, Health Professional, Pharmacy

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

Improper piercing and use of a needle greater than 21 gauge (larger internal diameter), while reconstituting the vial, can push rubber flecks into the solution. There were no grey flecks seen prior to the reconstitution of the vials and the issue was identified upon standard visual inspection prior to patient administration.

If injected, this product (containing rubber particulate matter from the stopper) could cause vein irritation/phlebitis or pulmonary embolic events that could result in permanent impairment of body function or damage to body structures, such as the lungs and vascular system. In addition, as ceftriaxone can be administered intramuscularly, the use of the product may result in local muscle inflammation and/or abscesses.

Ceftriaxone for Injection, USP, is used as a sterile, semi-synthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. It is used to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone sodium and other antibacterial drugs Ceftriaxone for Injection, USP, should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. To date, the Company has not received any reports of adverse events related to the recalled lots.

Ceftriaxone for Injection, USP, is packaged in a glass vial, in pack of 10, containing 10 vials in a carton, with NDC 68180-611-10, 68180-622-10, 68180-633-10, 68180-644-10 and as single pack containing one glass vial in a carton with NDC 68180-611-01, 68180-622-01, 68180-633-01.

The lots of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g included in the recall are listed in the table below:

Product NameNDCLot NumberExpiration Date
Ceftriaxone for Injection USP, 250mg68180-611-10C60018209/2019
68180-611-10C60013608/2019
68180-611-01C60014208/2019
68180-611-10C70014705/2020
68180-611-10C70020709/2020
Ceftriaxone for Injection USP, 500mg68180-622-01C60021809/2019
68180-622-10C60021909/2019
68180-622-10C60012608/2019
68180-622-10C60012708/2019
68180-622-10C60013708/2019
68180-622-10C60014308/2019
68180-622-01C60017308/2019
68180-622-10C70014605/2020
68180-622-10C70020809/2020
68180-622-10C70020909/2020
Ceftriaxone for Injection USP, 1g68180-633-10C60010605/2019
68180-633-10C60010805/2019
68180-633-01C60011005/2019
68180-633-10C60017409/2019
68180-633-10C60017909/2019
68180-633-10C60018009/2019
68180-633-10C60018109/2019
68180-633-10C70011003/2020
68180-633-10C70011103/2020
68180-633-10C70013105/2020
68180-633-10C70013205/2020
68180-633-10C70013805/2020
68180-633-01C70014305/2020
68180-633-10C60012808/2019
68180-633-01C60013008/2019
68180-633-10C60013808/2019
68180-633-10C70010803/2020
68180-633-10C70010903/2020
68180-633-10C70011203/2020
68180-633-10C70012905/2020
68180-633-10C70013005/2020
68180-633-10C70014205/2020
68180-633-10C70014505/2020
68180-633-01C70011303/2020
Ceftriaxone for Injection USP, 2g68180-644-10C60010905/2019
68180-644-10C60012908/2019
68180-644-10C60013508/2019

Ceftriaxone for Injection, USP, 250mg, Ceftriaxone for Injection, USP, 500mg, Ceftriaxone for Injection, USP, 1g and Ceftriaxone for Injection, USP, 2g were distributed Nationwide to Wholesalers / Drug chains.

Lupin Pharmaceuticals Inc. is notifying its distributors by phone and through recall notification and is arranging for return of all recalled product lots.

Hospitals / Physicians that have Ceftriaxone for Injection, USP, which are being recalled should stop using and return to Genco Pharmaceuticals Services “a subsidiary of FedEx Supply Chain” 6101 North 64th Street, Milwaukee, WI 53218, Tel: (855) 838-5786.

Questions regarding this recall can be made by contacting GENCO Pharmaceutical Services at 1-855-838-5786 Monday – Friday 7:30 am to 6:00 pm EST. For reimbursement, please have the recalled lots returned to GENCO, the lot number can be found on the side of the vial. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Ceftriaxone (marketed as Rocephin and generics)

Apr 14, 2009

Audience: Neonatology, infectious disease healthcare professionals, hospital risk managers

[Posted 04/14/2009] FDA notified healthcare professionals of an update to a previous alert that addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. At the request of FDA, the manufacturer of ceftriaxone (Roche) conducted two in vitro studies to assess the potential for precipitation of ceftriaxone-calcium when ceftriaxone and calcium-containing products are mixed in vials and in infusion lines. These two in vitro studies were conducted in neonatal and adult plasma to assess the potential for precipitation of ceftriaxone-calcium using varying ceftriaxone and calcium concentrations, including concentrations in excess of those achieved in vivo. Based on the results from these studies, FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary recommendations noted because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another.

[April 14, 2009 - Information for Healthcare Professionals - Ceftriaxone - FDA]

More ceftriaxone Resources